| Drug General Information |
| Drug ID |
D0Z2FD
|
| Former ID |
DCL001166
|
| Drug Name |
BMS-908662
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1],
[2]
|
|---|
| Company |
Exelixis; Bristol-Myers Squibb
|
| Structure |
|
Download
2D MOL
|
| Formula |
C24H19ClN4O4
|
| InChI |
InChI=1S/C24H19ClN4O4/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2/h3-12,32H,1-2H3,(H2,26,27,28,31)
|
| InChIKey |
MMNNTJYFHUDSKL-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
B-Raf proto-oncogene serine/threonine-protein kinase |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
FoxO signaling pathway
|
|
mTOR signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Focal adhesion
|
|
Natural killer cell mediated cytotoxicity
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Serotonergic synapse
|
|
Long-term depression
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Alcoholism
|
|
Hepatitis C
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Thyroid cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
IL-7 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Integrin signalling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
CDC42 signaling events
|
|
mTOR signaling pathway
|
|
Ras signaling in the CD4+ TCR pathway
|
|
ErbB1 downstream signaling
|
|
PDGFR-beta signaling pathway
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
Spry regulation of FGF signaling
|
|
Frs2-mediated activation
|
|
ARMS-mediated activation
|
|
CREB phosphorylation through the activation of Ras
|
|
RAF activation
|
|
MAP2K and MAPK activation
|
|
Negative feedback regulation of MAPK pathway
|
|
Negative regulation of MAPK pathway
|
|
WikiPathways
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
Estrogen signaling pathway
|
|
Senescence and Autophagy in Cancer
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
Focal Adhesion
|
|
Bladder Cancer
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Polycystic Kidney Disease Pathway
|
|
Corticotropin-releasing hormone
|
|
B Cell Receptor Signaling Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by FGFR
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Integrin-mediated Cell Adhesion
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7968). |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Exelixis (2011). |
|---|
